CXCR4 and neoplasm: CXCR4 inhibitors like plerixafor eradicate dormant tumor cells. PARP inhibitors (e.g., olaparib) combined with abiraterone reduce progression risk by 34% (268). Neoantigen vaccines (NeoVax) achieve 82% five-year metastasis-free survival.